NIH associate director announces departure to private sector, joining anti-aging biotech
The associate director of the National Institute of Health’s Office of Legislative Policy and Analysis (OLPA) is leaving her government post to join CEO James Peyer at Cambrian BioPharma.
Adrienne Hallett made the announcement via her LinkedIn profile Wednesday morning, linking to a statement from acting NIH director Lawrence Tabak.
In her role at OLPA, Hallett oversaw and managed representing biomedical research to Congress and presidential administrations, on top of leading 120 staff in advancing policy goals, coordinating responses to oversight investigations and more.
Tabak’s statement noted Hallett’s work in Congress, touting her record improving NIH’s federal appropriations by more than 40% since she started working for the agency in 2015.
“I want to thank Adrienne for her dedication to cultivating NIH’s relationship with Congress over the past several years,” Tabak said.
Beyond that, Tabak added that Hallett played a critical role as an advisor to NIH brass as the agency implemented sexual harassment reporting requirements, new standards relating to patient confidentiality and addressed structural racism in biomedical research.
Before her time at NIH, she worked with the US Senate’s appropriations committee for 14 years, moving up to staff director on the Labor, HHS, and Education subcommittee and later a senior policy advisor before moving to NIH.
As for her new gig, she will be leaving for Cambrian on Feb. 25 to become the biotech’s new VP of global policy and strategic initiatives.
Cambrian CEO James Peyer told Endpoints News that he first connected with Hallett through a mutual friend.
“We started talking about a year ago,” Peyer said, adding that Hallett will be working with foundations, government institutions and other groups for investments into Cambrian’s pipeline, along with long-term objectives such as being able to run more primary prevention trials.
“Her job will be to help us figure out how to run trials and how to find great partners,” Peyer added.
This announcement is the newest development for the company, less than two weeks after unwrapping Cambrian’s newest pipeline company, Isterian Biotech, which is currently focused on inhibitor drugs for TG2, a hard-to-target protein that could have impact in the extracellular space.